XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue by Product
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Revenue by Product Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (the “CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total product sales by these products: 
Three Months Ended September 30,Nine Months Ended September 30,
Product Sales by Product:2020201920202019
Bloxiverz$— $1,466 $2,201 $6,392 
Vazculep— 8,786 10,429 27,669 
Akovaz— 4,208 9,545 13,946 
Other— (231)159 213 
Total product sales$— $14,229 $22,334 $48,220 
On June 30, 2020, we sold the Hospital Products. See Note 4: Disposition of the Hospital Products.